Huo Xiang Zheng Qi Oral Liquid Combined with 5-HT3 Receptor Antagonists and Dexamethasone Can Prevent Chemotherapy-Induced Nausea and Vomiting for Patients Receiving Multiday Cisplatin-Based Regimen: A Multicenter Trial

医学 化疗引起恶心呕吐 养生 恶心 呕吐 地塞米松 内科学 临床终点 安慰剂 不利影响 随机对照试验 止吐药 麻醉 替代医学 病理
作者
Hao Wei,Yu Sun,Lingling Xie,Yuming Jia,Jun He,Xiaofei Deng,Wei Huang,Yang Hu,Jiang Zhu
出处
期刊:Journal of integrative and complementary medicine [Mary Ann Liebert]
卷期号:29 (8): 501-509 被引量:3
标识
DOI:10.1089/jicm.2022.0672
摘要

Background: Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing side effects associated with deterioration in the quality of life. This study aimed to assess the clinical value of Huoxiang Zhengqi (HXZQ) oral liquid, a Chinese patent medicine, in combination with 5-HT3 receptor antagonists (RAs) and dexamethasone, in preventing CINV in patients receiving multiday cisplatin-based chemotherapy. Methods: In this multicenter, exploratory randomized clinical trial, the authors compared the efficacy of HXZQ oral liquid against a control group receiving a placebo, in combination with 5-HT3 RAs and dexamethasone, in preventing CINV in chemotherapy-naive patients receiving a multiday cisplatin-based regimen between January 2021 and September 2021. The primary endpoint was the complete response (CR) rate. The secondary endpoints included days with no CINV, the incidence of CINV, and life function. Results: Sixty patients were randomized into two groups and included in the study. The CR rate was significantly improved by HXZQ oral liquid in acute CINV (63.33% vs. 33.33%, p = 0.020) and CINV beyond the risk phase (96.67% vs. 46.67%, p = 0.000). The number of days with no CINV was significantly more in the HXZQ group compared with the control group in the overall phase (18.10 ± 3.64 vs. 12.13 ± 7.63, p = 0.002). Significantly higher Functional Living Index-Emesis total and domain scores were observed in the HXZQ group. Conclusions: HXZQ oral liquid combined with 5-HT3 RAs and dexamethasone is a feasible and safe approach to prevent CINV in patients receiving multiday cisplatin-based chemotherapy who cannot use neurokinin 1 RAs. Clinical Trial Registration: ChiCTR2000040123
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
繁荣的映雁完成签到,获得积分10
1秒前
3秒前
爆米花应助风中泰坦采纳,获得10
4秒前
Singularity应助勤奋的寒荷采纳,获得10
5秒前
wangting完成签到,获得积分10
5秒前
慕青应助鱼的宇宙采纳,获得10
6秒前
流云完成签到 ,获得积分10
9秒前
10秒前
时泰完成签到,获得积分10
11秒前
领导范儿应助球球了采纳,获得10
11秒前
11秒前
13秒前
自觉完成签到,获得积分20
16秒前
刻苦惊蛰完成签到 ,获得积分10
17秒前
17秒前
惜惜发布了新的文献求助10
17秒前
19秒前
丰盛的煎饼应助安醉香采纳,获得10
20秒前
陈洋发布了新的文献求助10
24秒前
willnot完成签到,获得积分10
24秒前
26秒前
LLY发布了新的文献求助10
26秒前
赘婿应助圆圆努力中采纳,获得10
27秒前
鱼的宇宙发布了新的文献求助10
27秒前
脑洞疼应助圆圆努力中采纳,获得10
27秒前
所所应助圆圆努力中采纳,获得10
27秒前
情怀应助圆圆努力中采纳,获得10
27秒前
一米SQ完成签到 ,获得积分10
27秒前
Lucas应助LBF在努力成长采纳,获得10
31秒前
33秒前
惜惜完成签到,获得积分10
33秒前
36秒前
36秒前
36秒前
36秒前
37秒前
38秒前
cxc完成签到,获得积分20
38秒前
zho关闭了zho文献求助
40秒前
球球了完成签到,获得积分10
40秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3057507
求助须知:如何正确求助?哪些是违规求助? 2713919
关于积分的说明 7438319
捐赠科研通 2359130
什么是DOI,文献DOI怎么找? 1249728
科研通“疑难数据库(出版商)”最低求助积分说明 607254
版权声明 596328